CEBPA and neoplasm: This observation, together with the fact that the loss of CEBPA expression causes an increase in the tumor MDSC and immunosuppressive environment [3], led to the hypothesis that the clinical efficacy of MTL-CEBPA may be further augmented by therapies that synergistically influence the TIME to produce an enhanced immune response to the tumor.